Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single Center, Open, Single Arm Phase II Clinical Study of Fruquintinib in the Treatment of Soft Tissue Sarcoma

Next Previous
X
Search
Trial Profile

Single Center, Open, Single Arm Phase II Clinical Study of Fruquintinib in the Treatment of Soft Tissue Sarcoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fruquintinib (Primary)
  • Indications Haemangioendothelioma; Haemangiosarcoma; Soft tissue sarcoma; Solitary-fibrous-tumour
  • Focus Therapeutic Use

    • Most Recent Events

    • 09 Sep 2024 According to HUTCHMED media release, the data of this trial will be presented at the the European Society for Medical Oncology (ESMO) Congress 2024, taking place in Barcelona, Spain.
    • 06 Jun 2023 Results (Data cutoff: 31 January 2023; n=14) presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
    • 08 Dec 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top